Ansa Biotechnologies

ansabio.com →

-59%

est. 2Y upside i

HealthcareSeries B

Next-generation DNA synthesis using enzymes

Rank

#1236

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Ansa Biotechnologies operates in a rapidly expanding enzymatic DNA synthesis market with a compelling, differentiated technology for ultra-long and complex DNA, backed by an on-time guarantee.

Last updated: March 10, 2026

Bull (20%)+300%

Ansa's proprietary enzymatic synthesis platform, particularly its ultra-long (50kb) and sequence-perfect DNA with an industry-first on-time guarantee, gains significant traction, capturing substantial market share from traditional chemical synthesis and outcompeting other enzymatic players like DNA Script. Revenue scales to over $150M by 2028, justifying a valuation of $1B+.

Base (40%)+100%

Ansa maintains its differentiated position in the growing enzymatic DNA synthesis market, leveraging its unique capabilities for complex and ultra-long sequences while facing steady competition from established players and other enzymatic synthesis companies. It achieves consistent customer adoption and expands its product offerings, reaching approximately $50M in revenue by 2028 and a valuation of $500M.

Bear (40%)-60%

Intense competition from well-funded enzymatic players like DNA Script and aggressive moves by incumbents like Twist Bioscience erode Ansa's market share and pricing power, or technical challenges in scaling production limit growth. Revenue stalls at $25M, leading to a down round and a valuation of $100M, which would significantly diminish common stock value given the substantial liquidation preferences.

Est. time to liquidity~3.5 years

Preference Stack Risk

severe

Funding Intensity

51%

Investors have put in $136M in total funding. In an exit at or below the current $266M valuation, common stock holders would be behind $136M in liquidation preferences.

Dilution Risk

high

As a Series B company in a very capital-intensive sector with relatively low current revenue, Ansa will likely require additional significant funding rounds, leading to further dilution for existing equity holders.

Secondary Liquidity

active

EquityZen facilitates secondary market transactions for Ansa Biotechnologies stock, offering some liquidity for existing shareholders.

View all 6 open roles at Ansa Biotechnologies →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Ansa Biotechnologies's data — designed to show you've done your homework.

  • 1

    “Given DNA Script's significant funding and focus on enzymatic DNA synthesis, how does Ansa plan to further differentiate and maintain its competitive edge, particularly in scaling production and expanding its product portfolio beyond ultra-long sequences?”

  • 2

    “With current revenue estimated between $9M-$19.7M and a $266M valuation, what are the key milestones and revenue targets Ansa aims to achieve over the next 12-24 months to justify its current valuation and attract future funding at an increased valuation?”

  • 3

    “Considering the substantial liquidation preferences ($136M on a $266M valuation), how does Ansa envision a liquidity event (IPO or acquisition) that would provide meaningful returns for common stock holders, and what is the estimated timeline for such an event?”

Community

Valuation Sentiment

Our model estimates -59% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.